Preliminary trial of specific targeting therapy against malignant glioma
- PMID: 1968115
- DOI: 10.1016/0140-6736(90)90205-j
Preliminary trial of specific targeting therapy against malignant glioma
Abstract
The results of specific targeting therapy by use of lymphokine-activated killer (LAK) cells treated with bispecific antibody in 10 patients with malignant glioma were compared with the results of therapy with untreated LAK cells in 10 other patients. Both treated and untreated cells were given locally. The bispecific antibody was an anti-CD3 monoclonal antibody (mAb) chemically conjugated to anti-glioma mAb. Of the 10 patients given specific targeting therapy, 4 showed regression of tumour, and in another 4 patients computed tomography and histology suggested eradication of the glioma cells left behind after surgery. No recurrence was detected in the 10 to 18 months of follow-up. Patients receiving untreated LAK cells had recurrences within 1 year except in 1 case, and 8 patients died within 4 years. So far specific targeting therapy seems to be a new useful form of adoptive immunotherapy.
Similar articles
-
[Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].No Shinkei Geka. 1990 Nov;18(11):1001-6. No Shinkei Geka. 1990. PMID: 2247192 Japanese.
-
Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.J Immunol. 1992 Jan 1;148(1):285-91. J Immunol. 1992. PMID: 1345787
-
Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells.J Neurosurg. 1990 Mar;72(3):476-81. doi: 10.3171/jns.1990.72.3.0476. J Neurosurg. 1990. PMID: 2137533
-
[Immunotherapy for malignant glioblastoma].No Shinkei Geka. 1995 Mar;23(3):195-206. No Shinkei Geka. 1995. PMID: 7700486 Review. Japanese. No abstract available.
-
[Cellular immunotherapy for malignant glioma].Nihon Rinsho. 2005 Sep;63 Suppl 9:557-62. Nihon Rinsho. 2005. PMID: 16201581 Review. Japanese. No abstract available.
Cited by
-
Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.Immunology. 1994 Jan;81(1):92-5. Immunology. 1994. PMID: 7510664 Free PMC article.
-
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.Cancer Immunol Immunother. 1994 Sep;39(3):193-7. doi: 10.1007/BF01533386. Cancer Immunol Immunother. 1994. PMID: 7923250 Free PMC article. Clinical Trial.
-
Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.J Neurooncol. 1993 Feb;15(2):97-112. doi: 10.1007/BF01053931. J Neurooncol. 1993. PMID: 8509824
-
Management of primary malignant brain tumours.J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):2-5. doi: 10.1136/jnnp.60.1.2. J Neurol Neurosurg Psychiatry. 1996. PMID: 8558144 Free PMC article. Review. No abstract available.
-
Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.MAbs. 2016 May-Jun;8(4):799-810. doi: 10.1080/19420862.2016.1155014. Epub 2016 Feb 24. MAbs. 2016. PMID: 26910291 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
